These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
544 related articles for article (PubMed ID: 32280965)
1. Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience. Honap S; Chee D; Chapman TP; Patel M; Kent AJ; Ray S; Sharma E; Kennedy J; Cripps S; Walsh A; Goodhand JR; Ahmad T; Satsangi J; Irving PM; Kennedy NA; J Crohns Colitis; 2020 Oct; 14(10):1385-1393. PubMed ID: 32280965 [TBL] [Abstract][Full Text] [Related]
2. Short-term effectiveness and safety of tofacitinib in ulcerative colitis - real world data from tertiary medical centers in Israel. Avni-Biron I; Bar-Gil Shitrit A; Koslowsky B; Levartovsky A; Kopylov U; Weisshof R; Aviv Cohen N; Maharshak N; Hovel D; Israeli E; Naftali T; Goren I; Snir Y; Ollech JE; Banai-Eran H; Broitman Y; Sharar-Fischler T; Dotan I; Yanai H Dig Liver Dis; 2022 Feb; 54(2):192-197. PubMed ID: 34887214 [TBL] [Abstract][Full Text] [Related]
3. Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry. Chaparro M; Garre A; Mesonero F; Rodríguez C; Barreiro-de Acosta M; Martínez-Cadilla J; Arroyo MT; Manceñido N; Sierra-Ausín M; Vera-Mendoza I; Casanova MJ; Nos P; González-Muñoza C; Martínez T; Boscá-Watts M; Calafat M; Busquets D; Girona E; Llaó J; Martín-Arranz MD; Piqueras M; Ramos L; Surís G; Bermejo F; Carbajo AY; Casas-Deza D; Fernández-Clotet A; García MJ; Ginard D; Gutiérrez-Casbas A; Hernández L; Lucendo AJ; Márquez L; Merino-Ochoa O; Rancel FJ; Taxonera C; López Sanromán A; Rubio S; Domènech E; Gisbert JP J Crohns Colitis; 2021 Jan; 15(1):35-42. PubMed ID: 32969471 [TBL] [Abstract][Full Text] [Related]
4. Real-World Experience with Tofacitinib in IBD at a Tertiary Center. Weisshof R; Aharoni Golan M; Sossenheimer PH; El Jurdi K; Ollech JE; Pekow J; Cohen RD; Sakuraba A; Dalal S; Rubin DT Dig Dis Sci; 2019 Jul; 64(7):1945-1951. PubMed ID: 30734234 [TBL] [Abstract][Full Text] [Related]
5. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. Lair-Mehiri L; Stefanescu C; Vaysse T; Laharie D; Roblin X; Rosa I; Treton X; Abitbol V; Amiot A; Bouguen G; Dib N; Fumery M; Pariente B; Carbonnel F; Peyrin-Biroulet L; Simon M; Viennot S; Bouhnik Y Dig Liver Dis; 2020 Mar; 52(3):268-273. PubMed ID: 31732444 [TBL] [Abstract][Full Text] [Related]
6. Real-world clinical efficacy of tofacitinib in moderate-to-severe ulcerative colitis. Lopes SR; Martins C; Teixeira M; Tomás D World J Gastroenterol; 2024 Sep; 30(34):3929-3931. PubMed ID: 39350781 [TBL] [Abstract][Full Text] [Related]
7. Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial. Mukherjee A; Hazra A; Smith MK; Martin SW; Mould DR; Su C; Niezychowski W Br J Clin Pharmacol; 2018 Jun; 84(6):1136-1145. PubMed ID: 29377257 [TBL] [Abstract][Full Text] [Related]
8. Effect of Tofacitinib on One-Year Colectomy Risk in Anti-TNF Refractory Ulcerative Colitis: A Prospective Multicenter Italian Study. Carvalhas Gabrielli AM; Ferretti F; Monico CM; Tombetti E; Maconi G; Romeo S; Piazza O Sed N; Caprioli F; Mazzola AM; Alicante S; Bertè R; Lolli E; Scribano ML; Buscarini E; Ricci C; Carmagnola S; Ardizzone S; Cannatelli R Dig Dis Sci; 2024 May; 69(5):1785-1792. PubMed ID: 38530500 [TBL] [Abstract][Full Text] [Related]
9. Safety and effectiveness of tofacitinib in Korean adult patients with ulcerative colitis: post-marketing surveillance study. Yoon H; Ye BD; Kang SB; Lee KM; Choi CH; Jo JY; Woo J; Cheon JH BMC Gastroenterol; 2024 Aug; 24(1):273. PubMed ID: 39160459 [TBL] [Abstract][Full Text] [Related]
10. Real-world efficacy and safety of tofacitinib treatment in Asian patients with ulcerative colitis. Kojima K; Watanabe K; Kawai M; Yagi S; Kaku K; Ikenouchi M; Sato T; Kamikozuru K; Yokoyama Y; Takagawa T; Shimizu M; Shinzaki S World J Gastroenterol; 2024 Apr; 30(13):1871-1886. PubMed ID: 38659488 [TBL] [Abstract][Full Text] [Related]
11. Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry. Biemans VBC; Sleutjes JAM; de Vries AC; Bodelier AGL; Dijkstra G; Oldenburg B; Löwenberg M; van Bodegraven AA; van der Meulen-de Jong AE; de Boer NKH; Srivastava N; West RL; Römkens TEH; Horjus Talabur Horje CS; Jansen JM; van der Woude CJ; Hoekstra J; Weersma RK; van Schaik FDM; Hoentjen F; Pierik MJ; Aliment Pharmacol Ther; 2020 May; 51(9):880-888. PubMed ID: 32237087 [TBL] [Abstract][Full Text] [Related]
12. Real-world clinical and endoscopic outcomes after one year tofacitinib treatment in ulcerative colitis. Straatmijer T; van Gennep S; Duijvestein M; Ponsioen CIJ; Gecse KB; D'Haens GR; Löwenberg M Eur J Gastroenterol Hepatol; 2021 Oct; 33(10):1288-1297. PubMed ID: 33405424 [TBL] [Abstract][Full Text] [Related]
13. Clinical and Endoscopic Outcomes Through 78 Weeks of Tofacitinib Therapy for Ulcerative Colitis in a US Cohort. Dalal RS; Sharma PP; Bains K; Pruce JC; Allegretti JR Inflamm Bowel Dis; 2024 Oct; 30(10):1707-1713. PubMed ID: 37843044 [TBL] [Abstract][Full Text] [Related]
14. Real world evidence on the effectiveness and safety of tofacitinib in ulcerative colitis in Lebanon. Sharara AI; Alrazim A; Saniour P; Daniel F; Rached AA; Bahr A; Azar C; Geagea A; Ghoubar M BMC Gastroenterol; 2024 Oct; 24(1):349. PubMed ID: 39367371 [TBL] [Abstract][Full Text] [Related]
15. Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials. Sandborn WJ; Panés J; D'Haens GR; Sands BE; Su C; Moscariello M; Jones T; Pedersen R; Friedman GS; Lawendy N; Chan G Clin Gastroenterol Hepatol; 2019 Jul; 17(8):1541-1550. PubMed ID: 30476584 [TBL] [Abstract][Full Text] [Related]
16. Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme. Winthrop KL; Loftus EV; Baumgart DC; Reinisch W; Nduaka CI; Lawendy N; Chan G; Mundayat R; Friedman GS; Salese L; Thorpe AJ; Su C J Crohns Colitis; 2021 Jun; 15(6):914-929. PubMed ID: 33245746 [TBL] [Abstract][Full Text] [Related]
17. Tofacitinib is an effective treatment for moderate to severe ulcerative colitis, and intestinal ultrasound can discriminate response from non-response: a pragmatic prospective real-world study. Ollech JE; Eran-Banai H; Goren I; Sharar Fischler T; Avni-Biron I; Snir Y; Broitman Y; Cohen S; Friedenberg A; Pauker MH; Dotan I; Yanai H Ann Med; 2024 Dec; 56(1):2358183. PubMed ID: 38813808 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. Sands BE; Armuzzi A; Marshall JK; Lindsay JO; Sandborn WJ; Danese S; Panés J; Bressler B; Colombel JF; Lawendy N; Maller E; Zhang H; Chan G; Salese L; Tsilkos K; Marren A; Su C Aliment Pharmacol Ther; 2020 Jan; 51(2):271-280. PubMed ID: 31660640 [TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis. Vong C; Martin SW; Deng C; Xie R; Ito K; Su C; Sandborn WJ; Mukherjee A Clin Pharmacol Drug Dev; 2021 Mar; 10(3):229-240. PubMed ID: 33513294 [TBL] [Abstract][Full Text] [Related]
20. Modeling of Treatment Outcomes with Tofacitinib Maintenance Therapy in Patients with Ulcerative Colitis: A Post Hoc Analysis of Data from the OCTAVE Clinical Program. Chiorean M; Daperno M; Lees CW; Bonfanti G; Soudis D; Modesto I; Deuring JJ; Edwards RA Adv Ther; 2023 Oct; 40(10):4440-4459. PubMed ID: 37525075 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]